MX346957B - Agonistas de receptor de glp-1/glucagón de acción prolongada. - Google Patents

Agonistas de receptor de glp-1/glucagón de acción prolongada.

Info

Publication number
MX346957B
MX346957B MX2013014069A MX2013014069A MX346957B MX 346957 B MX346957 B MX 346957B MX 2013014069 A MX2013014069 A MX 2013014069A MX 2013014069 A MX2013014069 A MX 2013014069A MX 346957 B MX346957 B MX 346957B
Authority
MX
Mexico
Prior art keywords
receptor agonists
long
glucagon receptor
acting glp
glp
Prior art date
Application number
MX2013014069A
Other languages
English (en)
Other versions
MX2013014069A (es
Inventor
Eyal Fima Udi
Hershkovitz Oren
Original Assignee
Prolor Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolor Biotech Inc filed Critical Prolor Biotech Inc
Publication of MX2013014069A publication Critical patent/MX2013014069A/es
Publication of MX346957B publication Critical patent/MX346957B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere agonistas de receptor de GLP1/Glucagón pegilados y pegilados inversos incluyendo composiciones farmacéuticas comprendiendo los mismos y métodos para usar los mismos.
MX2013014069A 2011-06-02 2012-06-04 Agonistas de receptor de glp-1/glucagón de acción prolongada. MX346957B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492448P 2011-06-02 2011-06-02
US201261624589P 2012-04-16 2012-04-16
PCT/US2012/040744 WO2012167251A1 (en) 2011-06-02 2012-06-04 Long-acting glp-1/glucagon receptor agonists

Publications (2)

Publication Number Publication Date
MX2013014069A MX2013014069A (es) 2014-08-22
MX346957B true MX346957B (es) 2017-04-06

Family

ID=47259955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014069A MX346957B (es) 2011-06-02 2012-06-04 Agonistas de receptor de glp-1/glucagón de acción prolongada.

Country Status (16)

Country Link
US (1) US20140349922A1 (es)
EP (1) EP2714070B1 (es)
JP (1) JP6182134B2 (es)
KR (1) KR102092206B1 (es)
CN (1) CN104023739A (es)
AU (1) AU2012261869B2 (es)
BR (1) BR112013030933A2 (es)
CA (1) CA2837710C (es)
CL (1) CL2013003450A1 (es)
CO (1) CO6980619A2 (es)
EA (1) EA201391764A1 (es)
HK (1) HK1201478A1 (es)
IL (1) IL229732B (es)
MX (1) MX346957B (es)
SG (1) SG10201606243YA (es)
WO (1) WO2012167251A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
JP6290193B2 (ja) * 2012-06-04 2018-03-07 オプコ バイオロジクス リミテッド ペグ化ｏｘｍ変異体
BR122020018510B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3098235A4 (en) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
AU2016273045B2 (en) * 2015-05-29 2020-11-26 Opko Biologics Ltd. Pegylated oxyntomodulin variants
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
AR105284A1 (es) * 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP3368693A4 (en) * 2015-10-30 2019-03-27 The Research Foundation For The State University Of New York University at Buffalo OXYNTOMODULINE ANALOGUES AND METHODS OF PREPARATION AND USE
CN113456820B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
US20190160152A1 (en) * 2016-06-09 2019-05-30 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
AU2017296352A1 (en) 2016-07-11 2019-02-21 Opko Biologics Ltd. Long-acting coagulation factor VII and methods of producing same
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
US11376345B2 (en) 2017-11-23 2022-07-05 Sentigel Ab Hydrogel composition and its uses
US20200262887A1 (en) * 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
KR20210126088A (ko) 2019-02-11 2021-10-19 옵코 바이오로직스 리미티드 지속성 glp-2 유사체
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
WO2004089280A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
WO2007100535A2 (en) * 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
US8680263B2 (en) * 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
BRPI1013626B8 (pt) * 2009-03-20 2021-05-25 Hanmi Holdings Co Ltd método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad

Also Published As

Publication number Publication date
US20140349922A1 (en) 2014-11-27
CL2013003450A1 (es) 2015-01-16
BR112013030933A2 (pt) 2018-04-24
EP2714070B1 (en) 2024-03-20
KR102092206B1 (ko) 2020-03-24
KR20140083929A (ko) 2014-07-04
SG10201606243YA (en) 2016-09-29
EP2714070A4 (en) 2015-03-04
CA2837710A1 (en) 2012-12-06
WO2012167251A1 (en) 2012-12-06
HK1201478A1 (en) 2015-09-04
EA201391764A1 (ru) 2014-07-30
IL229732B (en) 2021-10-31
IL229732A0 (en) 2014-01-30
MX2013014069A (es) 2014-08-22
EP2714070A1 (en) 2014-04-09
CA2837710C (en) 2022-11-08
JP2014516993A (ja) 2014-07-17
JP6182134B2 (ja) 2017-08-16
CO6980619A2 (es) 2014-06-27
CN104023739A (zh) 2014-09-03
AU2012261869A1 (en) 2014-01-16
AU2012261869B2 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
MX346957B (es) Agonistas de receptor de glp-1/glucagón de acción prolongada.
HRP20181300T1 (hr) Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
ZA201804998B (en) Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
NZ612297A (en) Glucagon analogs exhibiting gip receptor activity
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX2013015176A (es) Co-agonistas del receptor de glucagon/glp-1.
AU2012273365A8 (en) Glucagon/GLP-1 receptor co-agonists
EP2718317A4 (en) GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
ZA201501694B (en) Exendin-4 derivatives as dual glp1/glucagon agonists
HK1198810A1 (en) Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP3377521A4 (en) LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
HK1201264A1 (en) Long-acting injectable moxidectin formulations and novel moxidectin crystal forms
EP3700550A4 (en) LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
ZA201209566B (en) Novel glucagon like peptide analogs,composition,and method of use
TN2013000524A1 (en) Glucagon/glp-1 receptor co-agonists
PT2866825T (pt) Uso de péptidos glp-1 de longa ação

Legal Events

Date Code Title Description
FG Grant or registration